Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renzapride - Atlantic Healthcare

Drug Profile

Renzapride - Atlantic Healthcare

Alternative Names: ATL-1251; AZM 112; BRL-24924; Renzapride hydrochloride

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Alizyme; Atlantic Healthcare; GlaxoSmithKline
  • Class Antifibrotics; Antiparkinsonians; Benzamides; Gastrokinetics; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cystic fibrosis; Gastroparesis; Parkinson's disease; Systemic scleroderma
  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Irritable bowel syndrome

Most Recent Events

  • 28 Nov 2023 Renzapride is still in phase I trials for Cystic-fibrosis in United Kingdom (Atlantic Healthcare pipeline, November 2023)
  • 28 Nov 2023 Renzapride is still in phase I trials for Systemic-scleroderma in United Kingdom (Atlantic Healthcare pipeline, November 2023)
  • 28 Feb 2023 No recent reports of development identified for phase-I development in Cystic-fibrosis in United Kingdom (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top